“In the pivotal 26- and 39-week oral repeat dose toxicity (RDT) studies in rats and dogs, respectively, ritlecitinib displayed reversible effects consistent with its intended pharmacology”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Pivotal GLP studies
26-week rat and 39-week dog oral repeat-dose studies
“In the pivotal 26- and 39-week oral repeat dose toxicity (RDT) studies in rats and dogs, respectively, ritlecitinib displayed reversible effects consistent with its intended pharmacology”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Route in tox
Oral
“In the pivotal 26- and 39-week oral repeat dose toxicity (RDT) studies in rats and dogs, respectively, ritlecitinib displayed reversible effects consistent with its intended pharmacology”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗